Skip to content
The Intraday Markets
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

OFIX Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

OFIX
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

OFIX Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

OFIX

$10.34
+$0.16 (1.57%)+1.57%
Closed
Loading chart...
IndexN/A
Market Cap0.42B
Enterprise Value0.75B
Income$-0.05B
Sales$0.19B
EmployeesN/A
P/E-13.51
P/S0.74
P/B1.34
P/C-472.73
EV/EBITDA-33.64
EV/SalesN/A
EPS (ttm)-0.77
EarningsN/A
Gross Margin67.09%
Oper. Margin-8.33%
Profit Margin-11.21%
Volume0.27M
Shs Outstand0.04B
Change1.57%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue$799.49M$746.64M$460.71M$464.48M$406.56M$459.95M$453.04M$433.82M
Cost of Revenue$253.61M$260.37M$123.54M$114.91M$101.89M$100.61M$96.63M$93.04M
Gross Profit$545.88M$486.27M$337.17M$349.56M$304.67M$359.35M$356.41M$340.79M
Gross Margin68.28%65.13%73.18%75.26%74.94%78.13%78.67%78.55%
Operating Expenses$630.50M$625.38M$350.44M$357.88M$310.94M$378.13M$326.32M$299.98M
Operating Income$-84.62M$-139.11M$-13.27M$-8.31M$-6.27M$-18.78M$30.09M$40.81M
Operating Margin-10.58%-18.63%-2.88%-1.79%-1.54%-4.08%6.64%9.41%
Net Income$-126.00M$-151.40M$-19.75M$-38.38M$2.52M$-28.46M$13.81M$6.22M
Net Margin-15.76%-20.28%-4.29%-8.26%0.62%-6.19%3.05%1.43%
EPS (Basic)$-3.30$-4.12$-0.98$-1.95$0.13$-1.51$0.75$0.34
EBITDAN/AN/AN/AN/AN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/AN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/AN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/AN/AN/AN/AN/A
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$893.29M$925.32M$458.63M$476.62M$525.86M$495.62M$466.64M$405.35M
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$390.17M$326.58M$121.77M$139.69M$169.00M$167.99M$131.24M$108.75M
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$503.12M$598.73M$336.86M$336.93M$356.86M$327.63M$335.40M$296.61M
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$503.12M$598.73M$336.86M$336.93M$356.86M$327.63M$335.40M$296.61M
Total Liabilities & Stockholders Equity$893.29M$925.32M$458.63M$476.62M$525.86M$495.62M$466.64M$405.35M
Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Tangible Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Return on EquityN/AN/AN/AN/AN/AN/AN/AN/A
Return on Invested CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/AN/AN/AN/A
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Net Income$-126.00M$-151.40M$-19.75M$-38.38M$2.52M$-28.46M$13.81M$6.22M
DepreciationN/AN/AN/AN/AN/AN/AN/AN/A
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$25.79M$-45.75M$-11.54M$18.48M$74.27M$32.03M$49.92M$53.34M
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/AN/A
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends PaidN/AN/AN/AN/AN/AN/AN/AN/A
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Mar 12 · 7:45AMOrthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor IntelligenceGlobeNewswire Inc. ↗Aug 6 · 2:16AMOrthofix (OFIX) Q2 Revenue Rises 2%The Motley Fool ↗Apr 10 · 5:30AMIntramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market InsightsGlobeNewswire Inc. ↗Feb 28 · 3:56PMProsthetic Disc Nucleus Market Outlook to Exceed US$ 265.8 Million by 2034, Driven by Minimally Invasive Surgery Innovations | Latest Report by Transparency Market Research Inc.GlobeNewswire Inc. ↗Nov 8 · 9:00PMOFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!GlobeNewswire Inc. ↗Oct 30 · 1:00AMORTHOFIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Orthofix Medical Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewswire Inc. ↗Oct 28 · 8:00PMOFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!GlobeNewswire Inc. ↗Oct 22 · 10:13PMOFIX CLASS ACTION NEWS: OrthoFix Medical Inc. Shareholders with Large Losses Should Seek Counsel; Contact Robbins LLP About the Pending Class Action LawsuitGlobeNewswire Inc. ↗
Show 12 more stories↓
Oct 21 · 7:51PMRLF, A TOP-RANKED LAW FIRM, Encourages Orthofix Medical Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – OFIXGlobeNewswire Inc. ↗Oct 21 · 5:16PMOFIX Investors Have Opportunity to Lead Orthofix Medical Inc. Securities Fraud Lawsuit with the Schall Law FirmBenzinga ↗Oct 21 · 2:03PMOFIX Investors Have Opportunity to Lead Orthofix Medical Inc. Securities Fraud Lawsuit Filed by the Schall Law FirmBenzinga ↗Oct 19 · 6:32PMRLF,資深投資者律師,鼓勵 Orthofix Medical Inc. 的投資者在重要的 10 月 21 日截止日期之前聘請法律顧問,以參加證券集體訴訟 – OFIXGlobeNewswire Inc. ↗Oct 17 · 9:18PMSHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors of the October 21, 2024 Lead Plaintiff Deadline in Class Action Lawsuits Filed on Behalf of DexCom, Inc. (DXCM), Orthofix Medical Inc. (OFIX), and Spire Global, Inc. (SPIR) ShareholdersGlobeNewswire Inc. ↗Oct 17 · 2:50AMORTHOFIX MEDICAL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orthofix Medical, Inc. - OFIXGlobeNewswire Inc. ↗Oct 16 · 7:18PMOFIX Investors: If You Sustained Significant Losses in Orthofix Medical Inc. Contact Shareholder Rights Law Firm Robbins LLP for Information About the Pending Class Action LawsuitGlobeNewswire Inc. ↗Oct 16 · 4:00PMGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orthofix Medical Inc. (OFIX)GlobeNewswire Inc. ↗Oct 16 · 4:42AMThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in Orthofix Medical Inc. Lawsuit – OFIXGlobeNewswire Inc. ↗Oct 16 · 2:19AMORTHOFIX MEDICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orthofix Medical, Inc. - OFIXGlobeNewswire Inc. ↗Oct 13 · 3:40AMROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Orthofix Medical Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – OFIXGlobeNewswire Inc. ↗Oct 11 · 2:46PMSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OrthofixGlobeNewswire Inc. ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
McPherron Aviva
Sell
3.7K
$9.38
$34K
Jun 18, 26
McPherron Aviva
Sell
3.7K
$9.38
$34K
Jun 18, 26
Paolucci Michael E
Award
15.0K
—
—
Jun 10, 26
Maniar Shweta
Award
15.0K
—
—
Jun 10, 26
BURRIS WAYNE
Award
15.0K
—
—
Jun 10, 26

Company

CEO: Massimo CalafioreEmployees: 1605www.orthofix.com
About the company↓

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.

Discover more

You may be interested in
MSFT

Microsoft Corp

$495.40

↓ 0.33%
CRM

Salesforce Inc

$196.21

↓ 2.56%
PYPL

PayPal Holdings Inc

$61.66

↑ 2.21%
AMZN

Amazon.com Inc

$262.65

↓ 0.75%
ABX

Abacus Global Management Inc

$9.27

↑ 8.80%
ADBE

Adobe Inc

$264.02

↓ 2.40%
JPM

JPMorgan Chase & Co

$362.84

↓ 0.14%
V

Visa Inc

$364.15

↓ 0.33%
GOOGL

Alphabet Inc

$345.90

↑ 0.30%
META

Meta Platforms Inc

$589.85

↓ 0.79%
ORCL

Oracle Corp

$150.52

↓ 3.49%
AMD

Advanced Micro Devices

$514.39

↑ 6.79%
The Intraday Markets

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC